^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Calquence (acalabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/25/2023
Excerpt:
Marginal Zone Lymphomas….Second-Line and Subsequent Therapy….Preferred regimens, BTK inhibitors...Acalabrutinib
